Arie Belldegrun

Q: What Schools Are Affiliated With Arie Belldegrun

Arie Belldegrun is affiliated with the following schools: Medical University of Vienna, Weizmann Institute of Science, MD Anderson Cancer Center, University of Verona, University of California, Los Angeles, Rennes 2 University, Hebrew University of Jerusalem, University of Washington

Arie Belldegrun's AcademicInfluence.com Rankings

Arie Belldegrun

Philosophy

#5603

World Rank

#8450

Historical Rank

#1443

USA Rank

Logic

#3400

World Rank

#4551

Historical Rank

#697

USA Rank

philosophy Degrees

Download Badge

Philosophy

Why Is Arie Belldegrun Influential?

(Suggest an Edit or Addition)

According to Wikipedia, Arie S. Belldegrun , FACS, is an Israeli-American urologic oncologist, billionaire businessman and investor. Early life and education Belldegrun was born in Tel Aviv, Israel. He received his medical degree from the Hadassah Medical Center at Hebrew University of Jerusalem in 1974, and conducted his post-graduate studies at the Weizmann Institute of Science in 1979. He completed his urologic surgery residency at Harvard Medical School in 1985, and his Surgical Oncology fellowship at the National Cancer Institute in 1988. He is certified by the American Board of Urology, and is a fellow of the American College of Surgeons and the American Association of Genitourinary Surgeons. Belldegrun is the director of the UCLA Institute of Urologic Oncology, professor of urology, and chief of the Division of Urologic Oncology at the David Geffen School of Medicine.

(See a Problem?)

Arie Belldegrun's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Guideline for management of the clinical T1 renal mass. (2009) (1718)
The changing natural history of renal cell carcinoma. (2001) (866)
Surveillance after radical or partial nephrectomy for localized renal cell carcinoma and management of recurrent disease. (2003) (715)
Improved prognostication of renal cell carcinoma using an integrated staging system. (2001) (673)
Carbonic anhydrase IX is an independent predictor of survival in advanced renal clear cell carcinoma: implications for prognosis and therapy. (2003) (665)
Safety and efficacy of partial nephrectomy for all T1 tumors based on an international multicenter experience. (2004) (607)
Risk group assessment and clinical outcome algorithm to predict the natural history of patients with surgically resected renal cell carcinoma. (2002) (592)
Prognostic indicators for renal cell carcinoma: a multivariate analysis of 643 patients using the revised 1997 TNM staging criteria. (2000) (459)
Prognostic value of histologic subtypes in renal cell carcinoma: a multicenter experience. (2006) (450)
Progression of metastatic human prostate cancer to androgen independence in immunodeficient SCID mice (1997) (427)
Phase II Study of Pomegranate Juice for Men with Rising Prostate-Specific Antigen following Surgery or Radiation for Prostate Cancer (2006) (418)
Renal cell carcinoma 2005: new frontiers in staging, prognostication and targeted molecular therapy. (2005) (366)
Use of the University of California Los Angeles integrated staging system to predict survival in renal cell carcinoma: an international multicenter study. (2004) (360)
Prognostic relevance of the mTOR pathway in renal cell carcinoma (2007) (357)
Renal cell carcinoma: prognostic significance of incidentally detected tumors. (2001) (334)
Interleukin 2 expanded tumor-infiltrating lymphocytes in human renal cell cancer: isolation, characterization, and antitumor activity. (1988) (322)
Evidence for clonal outgrowth of androgen-independent prostate cancer cells from androgen-dependent tumors through a two-step process. (1999) (315)
Efficacy of nephron-sparing surgery for renal cell carcinoma: analysis based on the new 1997 tumor-node-metastasis staging system. (1999) (303)
Prognostic Value of Histologic Subtypes in Renal Cell Carcinoma: A Multicenter Experience (2005) (303)
Renal cell carcinoma with retroperitoneal lymph nodes: role of lymph node dissection. (2003) (293)
Postoperative surveillance protocol for patients with localized and locally advanced renal cell carcinoma based on a validated prognostic nomogram and risk group stratification system. (2005) (293)
Pomegranate ellagitannin-derived metabolites inhibit prostate cancer growth and localize to the mouse prostate gland. (2007) (275)
Positive surgical margin appears to have negligible impact on survival of renal cell carcinomas treated by nephron-sparing surgery. (2010) (248)
Morbidity and clinical outcome of nephron-sparing surgery in relation to tumour size and indication. (2006) (234)
Preclinical and clinical evaluations of ABX-EGF, a fully human anti-epidermal growth factor receptor antibody. (2004) (224)
Using Protein Expressions to Predict Survival in Clear Cell Renal Carcinoma (2004) (223)
Prognostic significance of venous thrombus in renal cell carcinoma. Are renal vein and inferior vena cava involvement different? (2004) (216)
Multicenter, randomized, phase III trial of CD8(+) tumor-infiltrating lymphocytes in combination with recombinant interleukin-2 in metastatic renal cell carcinoma. (1999) (210)
Cytogenetic profile predicts prognosis of patients with clear cell renal cell carcinoma. (2009) (204)
Treatment of organ confined prostate cancer with third generation cryosurgery: preliminary multicenter experience. (2003) (204)
Novel approaches in the therapy of metastatic renal cell carcinoma (2005) (202)
Endogenous interleukin 6 is a resistance factor for cis-diamminedichloroplatinum and etoposide-mediated cytotoxicity of human prostate carcinoma cell lines. (1995) (198)
Selective blockade of androgenic steroid synthesis by novel lyase inhibitors as a therapeutic strategy for treating metastatic prostate cancer (2005) (197)
Tumor classification by tissue microarray profiling: random forest clustering applied to renal cell carcinoma (2005) (194)
Paraneoplastic signs and symptoms of renal cell carcinoma: implications for prognosis. (2003) (194)
Prognostic value of carbonic anhydrase IX and KI67 as predictors of survival for renal clear cell carcinoma. (2004) (193)
Pathobiology, prognosis, and targeted therapy for renal cell carcinoma: exploiting the hypoxia-induced pathway. (2003) (191)
Renal cell carcinoma with tumor thrombus extension: biology, role of nephrectomy and response to immunotherapy. (2003) (187)
A molecular classification of papillary renal cell carcinoma. (2005) (186)
Scoring algorithm to predict survival after nephrectomy and immunotherapy in patients with metastatic renal cell carcinoma (2003) (184)
Sarcomatoid renal cell carcinoma: biologic behavior, prognosis, and response to combined surgical resection and immunotherapy. (1999) (182)
Using tumor markers to predict the survival of patients with metastatic renal cell carcinoma. (2005) (178)
Low CAIX expression and absence of VHL gene mutation are associated with tumor aggressiveness and poor survival of clear cell renal cell carcinoma (2008) (176)
Molecular Signatures of Localized Clear Cell Renal Cell Carcinoma to Predict Disease-Free Survival after Nephrectomy (2009) (170)
Cytogenetic and Molecular Tumor Profiling for Type 1 and Type 2 Papillary Renal Cell Carcinoma (2009) (168)
Effects of interleukin-2 on renal function in patients receiving immunotherapy for advanced cancer. (1987) (165)
Overexpression of vimentin: role in the invasive phenotype in an androgen-independent model of prostate cancer. (2003) (164)
Clinicopathologic and molecular correlations of necrosis in the primary tumor of patients with renal cell carcinoma (2005) (163)
Neoadjuvant targeted therapy and advanced kidney cancer: observations and implications for a new treatment paradigm (2008) (163)
Surveillance strategies for renal cell carcinoma patients following nephrectomy. (2006) (161)
Secondary hormonal therapy for advanced prostate cancer. (2006) (159)
Hypoxia-Inducible Factor 1α in Clear Cell Renal Cell Carcinoma (2007) (158)
Is adrenalectomy a necessary component of radical nephrectomy? UCLA experience with 511 radical nephrectomies. (2000) (157)
Tumor size does not predict risk of metastatic disease or prognosis of small renal cell carcinomas. (2008) (156)
Prognostic factors for renal cell carcinoma with tumor thrombus extension. (2007) (155)
Treatment of metastatic renal cell carcinoma with nephrectomy, interleukin-2 and cytokine-primed or CD8(+) selected tumor infiltrating lymphocytes from primary tumor. (1997) (153)
Contemporary management of renal tumors with venous tumor thrombus. (2010) (152)
Reevaluation of the 1997 TNM classification for renal cell carcinoma: T1 and T2 cutoff point at 4.5 rather than 7 cm. better correlates with clinical outcome. (2001) (150)
Positron emission tomography in urological oncology. (1998) (145)
Renal cell carcinoma with retroperitoneal lymph nodes (2003) (145)
The effects of intentional cryoablation and radio frequency ablation of renal tissue involving the collecting system in a porcine model. (2005) (140)
Brain metastasis from renal cell carcinoma (2008) (135)
Collecting duct renal cell carcinoma: clinical study of a rare tumor. (2002) (135)
Pomegranate extract inhibits androgen-independent prostate cancer growth through a nuclear factor-κB-dependent mechanism (2008) (129)
The High-Dose Aldesleukin “Select” Trial: A Trial to Prospectively Validate Predictive Models of Response to Treatment in Patients with Metastatic Renal Cell Carcinoma (2014) (127)
Epithelial Cell Adhesion Molecule (KSA) Expression (2004) (127)
Number of metastatic sites rather than location dictates overall survival of patients with node-negative metastatic renal cell carcinoma. (2003) (124)
Concomitant administration of recombinant human interleukin-2 and recombinant interferon alfa-2A: an active outpatient regimen in metastatic renal cell carcinoma. (1992) (116)
Dose and Schedule Study of Panitumumab Monotherapy in Patients with Advanced Solid Malignancies (2008) (115)
Tumor biology and prognostic factors in renal cell carcinoma. (2011) (114)
Role of molecular markers in the diagnosis and therapy of renal cell carcinoma. (2005) (113)
Human tumor infiltrating lymphocytes. Analysis of lymphokine mRNA expression and relevance to cancer immunotherapy. (1989) (113)
Surveillance following radical or partial nephrectomy for renal cell carcinoma (2005) (112)
Chimeric PSA enhancers exhibit augmented activity in prostate cancer gene therapy vectors (2001) (111)
Epidermal growth factor receptor gene expression in normal human kidney and renal cell carcinoma. (1989) (111)
Adjuvant Weekly Girentuximab Following Nephrectomy for High-Risk Renal Cell Carcinoma: The ARISER Randomized Clinical Trial (2017) (107)
Novel therapeutic strategies for castration resistant prostate cancer: inhibition of persistent androgen production and androgen receptor mediated signaling. (2011) (107)
Mathematical model to predict individual survival for patients with renal cell carcinoma. (2002) (107)
Prognostic impact of preoperative neutrophil-to-lymphocyte ratio in localized nonclear cell renal cell carcinoma. (2013) (106)
Cytoreductive nephrectomy for kidney cancer with sarcomatoid histology--is up-front resection indicated and, if not, is it avoidable? (2009) (106)
Renal cell carcinoma: recent progress and future directions. (1997) (105)
Incidental renal tumors. (2000) (105)
Superficial bladder cancer: the role of interferon-alpha. (1998) (103)
Treatment of a glioblastoma patient by vaccination with autologous dendritic cells pulsed with allogeneic major histocompatibility complex class I-matched tumor peptides (2000) (101)
Prostate cryoablation using direct transperineal placement of ultrathin probes through a 17-gauge brachytherapy template-technique and preliminary results. (2001) (101)
Correlation of Ki-67 and gelsolin expression to clinical outcome in renal clear cell carcinoma. (2003) (101)
Adoptive cellular therapy. (2000) (100)
Genomic characterization of sarcomatoid transformation in clear cell renal cell carcinoma (2016) (99)
Interleukin 2 gene therapy for prostate cancer: phase I clinical trial and basic biology. (2001) (99)
PD-0332991, a potent and selective inhibitor of cyclin-dependent kinase 4/6, demonstrates inhibition of proliferation in renal cell carcinoma at nanomolar concentrations and molecular markers predict for sensitivity. (2013) (98)
p53 is an independent predictor of tumor recurrence and progression after nephrectomy in patients with localized renal cell carcinoma. (2005) (97)
In vivo cancer gene therapy with a recombinant interleukin-2 adenovirus vector. (1996) (97)
Changing concepts in the management of renal oncocytoma. (2002) (97)
Nephrectomy and interleukin-2 for metastatic renal-cell carcinoma. (2001) (97)
A Pilot Trial of Tumor Lysate-Loaded Dendritic Cells for the Treatment of Metastatic Renal Cell Carcinoma (2003) (94)
Immunotherapy for the Treatment of Urothelial Carcinoma (2017) (94)
Positron emission tomography in urologic oncology. (2002) (93)
Intraoperative thrombus embolization during nephrectomy and tumor thrombectomy: critical analysis of the University of California-Los Angeles experience. (2009) (90)
Prognostic relevance of tumour size in T3a renal cell carcinoma: a multicentre experience. (2007) (87)
Prevention of bladder cancer: a review. (2006) (87)
Tissue microarray analysis of cytoskeletal actin‐associated biomarkers gelsolin and E‐cadherin in urothelial carcinoma (2002) (87)
Impact of pathological tumour characteristics in patients with sarcomatoid renal cell carcinoma (2012) (86)
Cancer‐specific survival outcomes among patients treated during the cytokine era of kidney cancer (1989‐2005) (2008) (85)
Validation of an integrated staging system toward improved prognostication of patients with localized renal cell carcinoma in an international population. (2003) (82)
Human renal carcinoma line transfected with interleukin-2 and/or interferon alpha gene(s): implications for live cancer vaccines. (1993) (82)
Loss of CD10 (neutral endopeptidase) is a frequent and early event in human prostate cancer (2003) (81)
Pathobiology and prognosis of chromophobe renal cell carcinoma. (2008) (81)
In vitro modulation of tumor progression‐associated properties of hormone refractory prostate carcinoma cell lines by cytokines (1996) (79)
Interleukin-2-based immunotherapy for the treatment of metastatic renal cell carcinoma: an analysis of 203 consecutively treated patients. (1997) (77)
Chromosome 9p deletions identify an aggressive phenotype of clear cell renal cell carcinoma (2010) (76)
Unclassified renal cell carcinoma: clinical features and prognostic impact of a new histological subtype. (2002) (74)
Presence of tumor necrosis is not a significant predictor of survival in clear cell renal cell carcinoma: higher prognostic accuracy of extent based rather than presence/absence classification. (2009) (73)
Functional and oncological outcomes of partial nephrectomy of solitary kidneys. (2009) (73)
Cystic renal cell carcinoma: biology and clinical behavior. (2004) (73)
Cachexia-like symptoms predict a worse prognosis in localized t1 renal cell carcinoma. (2004) (73)
Cytokines alter target cell susceptibility to lysis. II. Evaluation of tumor infiltrating lymphocytes. (1989) (72)
The chemokine receptor CXCR3 is an independent prognostic factor in patients with localized clear cell renal cell carcinoma. (2007) (72)
Clinicopathological features and prognosis of synchronous bilateral renal cell carcinoma: an international multicentre experience (2007) (71)
Phase I Trial of Antigen-Specific Gene Therapy Using a Recombinant Vaccinia Virus Encoding MUC-1 and IL-2 in MUC-1-Positive Patients With Advanced Prostate Cancer (2004) (71)
Flap endonuclease 1 is overexpressed in prostate cancer and is associated with a high Gleason score (2006) (71)
Drug interactions between the proteasome inhibitor bortezomib and cytotoxic chemotherapy, tumor necrosis factor (TNF) alpha, and TNF-related apoptosis-inducing ligand in prostate cancer. (2003) (71)
Chemosensitization of human prostate carcinoma cell lines to anti-fas-mediated cytotoxicity and apoptosis. (1997) (70)
p21 is a prognostic marker for renal cell carcinoma: implications for novel therapeutic approaches. (2007) (69)
Renal cell carcinoma with tumor thrombus: is cytoreductive nephrectomy for advanced disease associated with an increased complication rate? (2002) (68)
Carbonic anhydrase IX in bladder cancer (2009) (68)
Prognostic relevance of capsular involvement and collecting system invasion in stage I and II renal cell carcinoma (2007) (68)
Predictive factors for ipsilateral recurrence after nephron-sparing surgery in renal cell carcinoma. (2008) (67)
Whole-body skeletal imaging in mice utilizing microPET: optimization of reproducibility and applications in animal models of bone disease (2002) (66)
Comparison of accuracy of 14‐, 18‐ and 20‐G needles in ex‐vivo renal mass biopsy: a prospective, blinded study (2010) (66)
Autologous Tumor-Specific Cytotoxicity of Tumor-Infiltrating Lymphocytes Derived from Human Renal Cell Carcinoma (1991) (65)
Immunosensitization of prostate carcinoma cell lines for lymphocytes (CTL, TIL, LAK)-mediated apoptosis via the Fas-Fas-ligand pathway of cytotoxicity. (1997) (64)
Basic research in kidney cancer. (2011) (63)
Prognostic impact of tumor size on pT2 renal cell carcinoma: an international multicenter experience. (2007) (63)
Metabolic and renal effects of interleukin-2 immunotherapy for metastatic cancer. (1988) (62)
Collecting system invasion in renal cell carcinoma: impact on prognosis and future staging strategies. (2003) (62)
Surveillance for renal cell carcinoma: why and how? When and how often? (2008) (61)
Dendritic Cell Surface Calreticulin Is a Receptor for NY-ESO-1: Direct Interactions between Tumor-Associated Antigen and the Innate Immune System1 (2006) (61)
Eastern Cooperative Oncology Group performance status predicts bone metastasis in patients presenting with renal cell carcinoma: implication for preoperative bone scans. (2004) (61)
Symptoms as well as tumor size provide prognostic information on patients with localized renal tumors. (2004) (61)
Actinomycin D and Gemcitabine Synergistically Sensitize Androgen-Independent Prostate Cancer Cells to Apo2L/TRAIL-Mediated Apoptosis (2001) (60)
Cytoreductive surgery in the management of metastatic renal cell carcinoma: the UCLA experience. (1996) (60)
The preoperative prognostic nutritional index is an independent predictor of survival in patients with renal cell carcinoma. (2015) (58)
Interferon-α Primed Tumor-Infiltrating Lymphocytes Combined with Interleukin-2 and Interferon-α as Therapy for Metastatic Renal Cell Carcinoma (1993) (58)
ARISER: A randomized double blind phase III study to evaluate adjuvant cG250 treatment versus placebo in patients with high-risk ccRCC—Results and implications for adjuvant clinical trials. (2013) (57)
WISH-PC2: a unique xenograft model of human prostatic small cell carcinoma. (2000) (57)
An association between renal cell carcinoma and lymphoid malignancies: A case series of eight patients (1996) (56)
Novel kidney cancer immunotherapy based on the granulocyte-macrophage colony-stimulating factor and carbonic anhydrase IX fusion gene. (2003) (55)
Conditional survival predictions after nephrectomy for renal cell carcinoma. (2009) (55)
Current management of renal cell carcinoma (1996) (55)
Updated results from a dose and schedule study of Panitumumab (ABX-EGF) monotherapy, in patients with advanced solid malignancies (2005) (54)
Tobacco smoking, GSTP1 polymorphism, and bladder carcinoma (2005) (54)
Treatment of a patient by vaccination with autologous dendritic cells pulsed with allogeneic major histocompatibility complex class I-matched tumor peptides. Case Report. (2000) (54)
Modulating BET Bromodomain Inhibitor ZEN‐3694 and Enzalutamide Combination Dosing in a Metastatic Prostate Cancer Patient Using CURATE.AI, an Artificial Intelligence Platform (2018) (53)
Interleukin-6 and renal cell cancer: Production, regulation, and growth effects (2005) (53)
Deletions of chromosomes 3p and 14q molecularly subclassify clear cell renal cell carcinoma (2013) (53)
CA9 gene: single nucleotide polymorphism predicts metastatic renal cell carcinoma prognosis. (2009) (53)
Cytoreductive Nephrectomy for Metastatic Renal Cell Carcinoma: Is It Still Imperative in the Era of Targeted Therapy? (2007) (52)
Quantitative Polymerase Chain Reaction Does not Improve Preoperative Prostate Cancer Staging: A Clinicopathological Molecular Analysis of 121 Patients (1998) (52)
Long-term outcomes of the surgical management of renal cell carcinoma (2006) (51)
Evolving principles of surgical management and prognostic factors for outcome in renal cell carcinoma. (2006) (50)
Validation of the ucla integrated staging system for patients with renal cell carcinoma. (2001) (50)
Lineage relationship between LNCaP and LNCaP‐derived prostate cancer cell lines (2004) (50)
Gain of chromosome 8q is associated with metastases and poor survival of patients with clear cell renal cell carcinoma (2012) (48)
Tissue Array-Based Predictions of Pathobiology, Prognosis, and Response to Treatment for Renal Cell Carcinoma Therapy (2004) (48)
Immunotherapy for renal cell carcinoma: the era of interleukin-2-based treatment. (1995) (47)
PC-SPES: herbal formulation for prostate cancer. (2002) (47)
Oncology : Adrenal / Renal / Upper Tract / Bladder Guideline for Management of the Clinical T 1 Renal Mass (46)
Histologic evaluation of metastases in renal cell carcinoma with sarcomatoid transformation and its implications for systemic therapy (2010) (45)
Associations between Variants of the 8q24 Chromosome and Nine Smoking-Related Cancer Sites (2008) (45)
Adjuvant Therapy for High Risk Localized Kidney Cancer: Emerging Evidence and Future Clinical Trials (2018) (45)
G250: A carbonic anhydrase IX monoclonal antibody (2005) (45)
Extrarenal angiomyolipomas of the perinephric space. (1992) (44)
Pathological, immunohistochemical and cytogenetic features of papillary renal cell carcinoma with clear cell features. (2011) (44)
Optimizing prostate cancer suicide gene therapy using herpes simplex virus thymidine kinase active site variants. (2002) (43)
Renal toxicity of interleukin-2 administration in patients with metastatic renal cell cancer: effect of pre-therapy nephrectomy. (1989) (43)
Single nucleotide polymorphisms of 8 inflammation‐related genes and their associations with smoking‐related cancers (2010) (43)
Protein Expression Profiles in Renal Cell Carcinoma: Staging, Prognosis, and Patient Selection for Clinical Trials (2007) (43)
The contemporary role of ablative treatment approaches in the management of renal cell carcinoma (RCC): focus on radiofrequency ablation (RFA), high-intensity focused ultrasound (HIFU), and cryoablation (2014) (42)
The effect of gender and age on kidney cancer survival: younger age is an independent prognostic factor in women with renal cell carcinoma. (2014) (42)
Salvage Cryotherapy for Radiation-Recurrent Prostate Cancer: Outcomes and Complications (2011) (42)
Prognostic variables to predict cancer‐related death in incidental renal tumours (2008) (41)
Minimally invasive ablative approaches in the treatment of renal cell carcinoma (2002) (41)
Smoking negatively impacts renal cell carcinoma overall and cancer‐specific survival (2012) (41)
Green Tea Extract Modulates Actin Remodeling via Rho Activity in an In vitro Multistep Carcinogenic Model (2005) (40)
Current staging of renal cell carcinoma. (2003) (40)
Dominant B cell epitope from NY‐ESO‐1 recognized by sera from a wide spectrum of cancer patients: Implications as a potential biomarker (2005) (40)
Partial Nephrectomy: A Contemporary Review Regarding Outcomes and Different Techniques (2008) (40)
Platelet count and preoperative haemoglobin do not significantly increase the performance of established predictors of renal cell carcinoma-specific mortality. (2007) (40)
Performance status and cytoreductive nephrectomy (2008) (39)
Primary and salvage cryotherapy for prostate cancer. (2010) (39)
Cardiopulmonary bypass and renal cell carcinoma with level IV tumour thrombus: can deep hypothermic circulatory arrest limit perioperative mortality? (2011) (39)
Cytoreductive nephron‐sparing surgery does not appear to undermine disease‐specific survival in patients with metastatic renal cell carcinoma (2007) (39)
Use of American Society of Anesthesiologists physical status classification to assess perioperative risk in patients undergoing radical nephrectomy for renal cell carcinoma. (2004) (39)
Unclassified renal cell carcinoma: an analysis of 85 cases (2007) (39)
Suramin in hormone-refractory metastatic prostate cancer: a drug with limited efficacy. (1996) (39)
Development and external validation of a nomogram predicting disease specific survival after nephrectomy for papillary renal cell carcinoma. (2010) (38)
Advances in immune-based therapies of renal cell carcinoma (2004) (37)
Metachronous Bilateral Renal Cell Carcinoma: Risk Assessment, Prognosis and Relevance of the Primary-Free Interval (2007) (37)
Blood loss and the need for transfusion in patients who undergo partial or radical nephrectomy for renal cell carcinoma. (2000) (37)
Oral bropirimine immunotherapy of bladder carcinoma in situ after prior intravesical bacille Calmette-Guérin. (1998) (37)
Prognostic value of microvascular invasion in predicting the cancer specific survival and risk of metastatic disease in renal cell carcinoma: a multicenter investigation. (2012) (37)
Annexin‐I as a potential target for green tea extract induced actin remodeling (2007) (36)
Carbonic anhydrase IX and renal cell carcinoma: prognosis, response to systemic therapy, and future vaccine strategies (2008) (36)
Carbonic anhydrase-IX score is a novel biomarker that predicts recurrence and survival for high-risk, nonmetastatic renal cell carcinoma: Data from the phase III ARISER clinical trial. (2015) (36)
Expanding the indications for surgery and adjuvant interleukin-2-based immunotherapy in patients with advanced renal cell carcinoma. (2000) (36)
Management and outcomes of tumor recurrence after focal ablation renal therapy. (2010) (35)
Cellular therapy: scientific rationale and clinical results in the treatment of metastatic renal-cell carcinoma. (1995) (35)
Fuhrman grade provides higher prognostic accuracy than nucleolar grade for papillary renal cell carcinoma. (2010) (35)
Understanding the natural biology of kidney cancer: implications for targeted cancer therapy. (2007) (35)
Absent CD44v6 expression is an independent predictor of poor urothelial bladder cancer outcome. (2010) (34)
Open partial nephrectomy for the treatment of renal cell carcinoma (2006) (34)
A phase 2 study of TMX-101, intravesical imiquimod, for the treatment of carcinoma in situ bladder cancer. (2017) (33)
Effect of L‐buthionine sulfoximine on the radiation response of human renal carcinoma cell lines (1993) (33)
Expression of CXCR3 on Mononuclear Cells and CXCR3 Ligands in Patients With Metastatic Renal Cell Carcinoma in Response to Systemic IL-2 Therapy (2007) (33)
Renal cell carcinoma: basic biology and current approaches to therapy. (1991) (33)
Biology of renal cell carcinoma: changing concepts in classification and staging. (2001) (33)
Words of wisdom. Re: Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. (2015) (32)
Erythropoietin production. A potential marker for interleukin‐2/interferon‐responsive tumors (1993) (32)
Carbonic anhydrase IX and the future of molecular markers in renal cell carcinoma (2005) (32)
CL1-SR39: A noninvasive molecular imaging model of prostate cancer suicide gene therapy using positron emission tomography. (2002) (31)
236: Carbonic Anhydrase IX (CAIX) in Bladder Cancer: A Diagnostic, Prognostic and Therapeutic Molecular Marker (2007) (31)
Phase-ii study of pomegranate juice for men with prostate cancer and increasing psa (2006) (31)
Bladder cancer 2000: molecular markers for the diagnosis of transitional cell carcinoma. (2001) (31)
The role of interferon and interleukin-2 in the immunotherapeutic approach to renal cell carcinoma. (1991) (31)
Clinical, molecular, and genetic correlates of lymphatic spread in clear cell renal cell carcinoma. (2012) (30)
Dendritic Cell–Based Immunotherapy in Prevention and Treatment of Renal Cell Carcinoma: Efficacy, Safety, and Activity of Ad-GM·CAIX in Immunocompetent Mouse Models (2013) (30)
Prognostic factors in renal cell carcinoma. (2006) (30)
Prognostic factors and molecular markers for renal cell carcinoma (2001) (30)
The chromophobe tumor grading system is the preferred grading scheme for chromophobe renal cell carcinoma. (2011) (30)
Generation of Kidney Cancer-Specific Antitumor Immune Responses Using Peripheral Blood Monocytes Transduced With a Recombinant Adenovirus Encoding Carbonic Anhydrase 9 (2004) (30)
Adjuvant therapy of renal cell carcinoma: patient selection and therapeutic options (2005) (29)
Poor prognosis and advanced clinicopathological features of clear cell renal cell carcinoma (ccRCC) are associated with cytoplasmic subcellular localisation of Hypoxia inducible factor-2α. (2014) (28)
Cryosurgical ablation of renal tumors using 1.5-millimeter, ultrathin cryoprobes. (2002) (28)
Recognizing the Continuous Nature of Expression Heterogeneity and Clinical Outcomes in Clear Cell Renal Cell Carcinoma (2016) (28)
Gene expression and tissue microarray analysis of interleukin-2 complete responders in patients with metastatic renal cell carcinoma (2005) (28)
Natural immune reactivity-associated therapeutic response in patients with metastatic renal cell carcinoma receiving tumor-infiltrating lymphocytes and interleukin-2-based therapy. (1996) (28)
Sustained-release Formulation of Mitomycin C to the Upper Urinary Tract Using a Thermosensitive Polymer: A Preclinical Study. (2017) (27)
Nephron-sparing surgery is superior to radical nephrectomy in preserving renal function benefit even when expanding indications beyond the traditional 4-cm cutoff. (2014) (27)
Tumor necrosis factor‐related apoptosis‐inducing ligand (TRAIL) for treatment of prostate cancer: first results and review of the literature (1999) (27)
The staging of renal cell carcinoma (2008) (25)
Role of surgical approach on lymph node dissection yield and survival in patients with upper tract urothelial carcinoma. (2018) (25)
Clear cell renal cell carcinoma: multiphasic multidetector CT imaging features help predict genetic karyotypes. (2011) (25)
Characterization of the mTOR pathway in renal cell carcinoma and its use in predicting patient selection for agents targeting this pathway (2005) (25)
Development of gene therapy for prostate cancer using a novel promoter of prostate-specific antigen. (1997) (25)
Heterogeneity of molecular targets on clonal cancer lines derived from a novel hormone‐refractory prostate cancer tumor system (2003) (25)
Mammalian target of rapamycin inhibitors in renal cell carcinoma: current status and future applications. (2006) (24)
Targeting the vascular endothelial growth factor pathway in renal cell carcinoma: A tissue array based analysis (2005) (24)
Atypical contrast reactions associated with systemic interleukin-2 therapy. (1991) (24)
Feasibility of nerve-sparing prostate cryosurgery: applications and limitations in a canine model. (2005) (23)
The effects of granulocyte-macrophage colony-stimulating factor on tumour-infiltrating lymphocytes from renal cell carcinoma. (1995) (23)
Joint association of polymorphism of the FGFR4 gene and mutation TP53 gene with bladder cancer prognosis (2006) (23)
Expression of the vascular endothelial growth factor family in tumor dissemination and disease free survival in clear cell renal cell carcinoma (2005) (23)
Staging of renal cell carcinoma: current concepts (2005) (22)
Systemic therapy for metastatic renal cell carcinoma: a review and update. (2012) (22)
Immunotherapy and gene therapy. (1996) (22)
Patterns of cytokine release of unselected and CD8+ selected renal cell carcinoma tumor-infiltrating lymphocytes (TIL). Evidence for enhanced specific killing of tumor necrosis factor-secreting/IL-6 nonsecreting TIL in vitro and correlation with complete response in vivo. (1994) (21)
The role of molecular markers in the staging of renal cell carcinoma (2007) (21)
Adjuvant treatment for renal cell carcinoma (2006) (21)
Treatment of metastatic renal cell carcinoma with high-dose bolus interleukin-2 in a non-intensive care unit: an analysis of 124 consecutively treated patients. (2001) (21)
In vivo efficacy of laparoscopic assisted percutaneous renal cryotherapy: evidence based guidelines for the practicing urologist. (2008) (20)
Immunosensitization of resistant human tumor cells to cytotoxicity by tumor infiltrating lymphocytes. (2003) (20)
Vaccine and gene therapy of renal cell carcinoma. (2001) (20)
Laparoscopic radical nephrectomy. (2001) (20)
Immunotherapy for advanced renal cell cancer: the role of radical nephrectomy. (1990) (20)
Body Mass Index and Survival in a Prospective Randomized Trial of Localized High-Risk Renal Cell Carcinoma (2016) (20)
Quality of pathological reporting for renal cell cancer: implications for systemic therapy, prognostication and surveillance (2011) (20)
The expression of C-jun and junB mRNA in renal cell cancer and in vitro regulation by transforming growth factor beta 1 and tumor necrosis factor alpha 1. (1992) (19)
LABAZ1: A metastatic tumor model for renal cell carcinoma expressing the carbonic anhydrase type 9 tumor antigen. (2003) (19)
Gene therapy--the future is here: a guide to the practicing urologist. (1998) (19)
Renal Cell Carcinoma: Prognostic Factors and Patient Selection (2007) (19)
Gene therapy for prostate cancer. New perspectives on an old problem. (1999) (19)
Serial retrograde instillations of sustained release formulation of mitomycin C to the upper urinary tract of the Yorkshire swine using a thermosensitive polymer: Safety and feasibility. (2017) (19)
Anti-tumor reactivity of human lymphokine activated killer (LAK) cells against fresh and cultured preparations of renal cell cancer. (1988) (18)
Renal cell carcinoma with tumor thrombus extension into the proximal pulmonary artery. (2003) (18)
Gene therapy for prostate cancer at the University of California, Los Angeles: preliminary results and future directions (2000) (18)
Primary leiomyosarcoma of the inferior vena cava presenting as a renal mass. (2004) (18)
New Perspectives in Prostate Cancer (1998) (18)
New biologicals for prostate cancer prevention: Genes, vaccines, and immune-based interventions. (2001) (18)
Metachronous bilateral renal cell carcinoma: risk assessment, prognosis and relevance of the primary-free interval. (2007) (18)
831: Phase II Study of Pomegranate Juice for Men with Rising PSA following Surgery or Radiation for Prostate Cancer (2005) (18)
Renal and adrenal tumors : biology and management (2002) (17)
Renal cell carcinoma: basic biology and clinical behavior. (1996) (17)
Interferon-alpha primed tumor-infiltrating lymphocytes combined with interleukin-2 and interferon-alpha as therapy for metastatic renal cell carcinoma. (1993) (17)
Immunomodulatory dendritic cells generated from nonfractionated bulk peripheral blood mononuclear cell cultures induce growth of cytotoxic T cells against renal cell carcinoma. (2000) (17)
Dendritic cell-based immunotherapy of renal cell carcinoma (2001) (16)
Carbonic Anhydrase IX Is an Independent Predictor of Survival in Advanced Renal Clear Cell Carcinoma (2003) (16)
Management of disseminated kidney cancer. (1994) (16)
Combination biologic therapy with interleukin-2 and interferon-alfa in the outpatient treatment of metastatic renal cell carcinoma. (1993) (16)
Sex, age, and surgeon decision on nephron-sparing surgery are independent predictors of renal masses with benign histologic findings--a multicenter survey. (2010) (16)
Ultrasound-based combination therapy: potential in urologic cancer (2011) (15)
Gene and immune therapy for renal cell carcinoma (2001) (14)
Proteomic identification of interleukin-2 therapy response in metastatic renal cell cancer. (2005) (14)
A novel resectoscope for transurethral resection of bladder tumors and the prostate. (2007) (14)
Carbonic anhydrase IX as a predictive biomarker for clear cell renal cell carcinoma. (2008) (13)
Soluble tumor necrosis factor receptor expression in patients with metastatic renal cell carcinoma treated with interleukin-2-based immunotherapy. (1993) (13)
Ki67, gelsolin and PTEN expression in sarcomatoid renal tumors (2003) (13)
RENCA/carbonic anhydrase-IX: a murine model of a carbonic anhydrase-IX-expressing renal cell carcinoma. (2006) (13)
Sarcomatoid renal cell carcinoma (2001) (13)
Transurethral incisions and resections under local anaesthesia. (1987) (13)
996: Prognostic Significance of T3A Renal Cell Carcinoma with Adrenal Gland Involvement: An International Multicenter Experience (2005) (13)
Metastatic renal cell cancer: interleukin-2 toxicity induced by contrast agent injection. (1991) (13)
Society of Urologic Oncology Biotechnology Forum: new approaches and targets for advanced prostate cancer. (2001) (12)
Sensitivity of human renal cell carcinoma lines to TNF, adriamycin, and combination: role of TNF mRNA induction in overcoming resistance. (1993) (12)
Emerging technologies in uroradiologic imaging. (2003) (12)
Salvage cryosurgery of the prostate after radiation failure. (2004) (12)
8q24 Amplification in Transitional Cell Carcinoma of Bladder (2003) (12)
Salvage-Targeted Kidney Cancer Therapy in Patients Progressing on High-Dose Interleukin-2 Immunotherapy: The UCLA Experience (2013) (12)
WISH-PC 2 : A Unique Xenograft Model of Human Prostatic Small Cell Carcinoma 1 (2000) (11)
Primary lymphoma of female urethra: long-term control by radiation therapy. (1993) (11)
The utility of PSA doubling time to monitor prostate cancer recurrence. (2001) (11)
Trends in usage of cytoreductive partial nephrectomy and effect on overall survival in patients with metastatic renal cell carcinoma. (2017) (11)
Interferon alpha for the treatment of superficial bladder cancer. (1999) (11)
1774: Nephron-Sparing Surgery as the New Gold Standard for T1 ≤ 7 CM) Renal Cell Carcinoma: Results of a Contemporary Ucla Series (2004) (11)
Adoptive immunotherapy of urologic tumors. (1989) (10)
Posterior lumbotomy: surgery for upper tract calculi. (1983) (10)
Effect of an epidermal growth factor receptor tyrosine kinase inhibitor on actin remodeling in an in vitro bladder cancer carcinogenesis model (2006) (10)
MP77-08 MITOGEL: OPTIMIZING DRUG DELIVERY TO THE UPPER URINARY TRACT—A PRECLINICAL EVALUATION (2014) (10)
Immunotherapy in Renal Cell Carcinoma; Cellular Immunotherapy (1996) (10)
Randomized phase II trial of maintenance sunitinib versus placebo following response to chemotherapy (CT) for patients (pts) with advanced urothelial carcinoma (UC). (2012) (10)
Hypoxia-Inducible Factor 1A in Clear Cell Renal Cell Carcinoma (2007) (10)
Array-based comparative genomic hybridization (CGH) identifies chromosomal imbalances between Interleukin-2 complete and non-responders (2008) (10)
Laparoscopic and percutaneous ablative techniques in the treatment of renal cell carcinoma. (2002) (10)
Tumor markers for the early detection of bladder cancer. (2002) (9)
Immune gene therapy for kidney cancer: the search for a magic trigger. (2003) (9)
Lymphokine mRNA profile and functional analysis of a human CD4+ clone with unique antitumor specificity isolated from renal cell carcinoma ascitic fluid (2005) (9)
RADICAL NEPHRECTOMY IS NOT SUPERIOR TO NEPHRON SPARING SURGERY IN PT1B-PT2N0M0 RENAL TUMOURS: A MATCHED COMPARISON ANALYSIS IN 546 CASES (2008) (9)
What to do about the incidentally found adrenal mass (1989) (9)
EFFECT OF INTERLEUKIN-2 (IL-2) GENE THERAPY ON PROSTATE SPECIFIC ANTIGEN IN PATIENTS UNDERGOING NEOADJUVANT OR ADJUVANT GENE THERAPY FOR PROSTATE CANCER (1999) (8)
501 NEPHRON-SPARING SURGERY AS THE NEW GOLD STANDARD FOR T1 (< 7 CM) RENAL CELL CARCINOMA: RESULTS OF A CONTEMPORARY UCLA SERIES. (2006) (8)
Commentary on Prognostic Factors in Renal Cell Carcinoma (1995) (8)
Open surgical management of renal cell carcinoma in the era of minimally invasive kidney surgery (2005) (8)
Phase I, open-label, single-center, multiple-dose, dose-escalation clinical study of SUO11248 (Sunitinib) in subjects with high-risk prostate cancer who have elected to undergo radical prostatectomy (2007) (8)
Prospective evaluation of carbonic anhydrase IX (CAIX) as a molecular marker in metastatic renal cell carcinoma (2007) (8)
665: Salvage Cryosurgical Ablation for Radiorecurrent Prostate Cancer Using Third Generation Cryoneedles: The University of California-Los Angeles Experience (2005) (8)
Immune and genetic therapies for advanced renal cell carcinoma. (2000) (8)
Phase I clinical trial of interleukin 2 (IL-2) gene therapy for prostate cancer (2001) (8)
Optimal dosing of ABX-EGF in cancer patients (2002) (7)
Induction of G 250-targeted and T-Cell-mediated Antitumor Activity against Renal Cell Carcinoma Using a Chimeric Fusion Protein Consisting of G 250 and Granulocyte / Monocyte-Colony Stimulating Factor (2001) (7)
Inhibitory effect of locally produced and exogenous interleukin-6 on tumor growth in vivo (1994) (7)
Synchronous RCC and TCC of the Kidney in a Patient With Multiple Recurrent Bladder Tumors. (1999) (7)
Complications of Adrenal Surgery (2007) (7)
Re: Presence of Tumor Necrosis is Not a Significant Predictor of Survival in Clear Cell Renal Cell Carcinoma: Higher Prognostic Accuracy of Extent Based Rather Than Presence/Absence Classification (2009) (6)
Carbonic anhydrase IX: role in diagnosis prognosis and cancer therapy. Introduction. (2008) (6)
740: Can PT2 Classification for Renal Cell Carcinoma be Improved? an International Multicenter Experience? (2006) (6)
The effects of interleukin-6 on tumor-infiltrating lymphocytes derived from human renal cell cancer. (1991) (6)
Update on partial nephrectomy and novel techniques. (2007) (6)
[How radical nephrectomy compares to partial nephrectomy for the treatment of pT1a papillary renal cell carcinomas?]. (2010) (6)
The treatment of patients with metastatic melanoma and renal cell cancer using in vitro expanded and genetically-engineered (neomycin phosphotransferase) bulk, CD8(+) and/or CD4(+) tumor infiltrating lymphocytes and bulk, CD8(+) and/or CD4(+) peripheral blood leukocytes in combination with recombina (1992) (6)
Differential diagnosis of hypercalcemia in renal malignancy. (2007) (6)
Immunotherapy of prostate cancer (2001) (6)
Modulation of tumor-infiltrating lymphocytes derived from human renal cell carcinoma by interleukin-4. (1992) (6)
Molecular-based therapies for renal cell carcinoma (2001) (6)
1651: Molecular Prognostic Modeling Using Protein Expression Profile in Clear Cell Renal Carcinoma (2004) (5)
Overall survival in patients with metastatic renal cell carcinoma and clinical N1 disease undergoing cytoreductive nephrectomy and lymph node dissection. (2017) (5)
COST EFFECTIVENESS OF FDG WHOLE BODY PET IN THE EVALUATION OF RENAL CELL CA (1995) (5)
Receptor activator of NF-κB (RANK)-mediated induction of metastatic spread and association with poor prognosis in renal cell carcinoma. (2018) (5)
Partial Nephrectomy for the Treatment of Renal Cell Carcinoma (5)
The sensitivity of testosterone immunoassays and their role in monitoring antiandrogen therapy. (2006) (5)
Immunotherapy for renal cell carcinoma. (1992) (4)
A Phase I, Open-label, Dose-escalation, and Cohort Expansion Study to Evaluate the Safety and Immune Response to Autologous Dendritic Cells Transduced With AdGMCA9 (DC-AdGMCAIX) in Patients With Metastatic Renal Cell Carcinoma (2020) (4)
A randomized phase III trial of high-dose interleukin-2 versus subcutaneous interleukin-2/interferon (2002) (4)
Late appearance of parathyroid adenoma in a renal transplant recipient with multiple primary malignancies. (1982) (4)
Basic biology and clinical behavior of renal cell carcinoma. (2003) (4)
The University of California, Los Angeles/Jennifer Jones Simon Foundation symposium on prostate cancer and epithelial cell biology: bringing together basic scientists and clinicians in the fight against advanced prostate cancer. (1998) (4)
PAPILLARY RENAL CELL CARCINOMA WITH CLEAR CELLS – PATHOLOGICAL, IMMUNOHISTOCHEMICAL AND CYTOGENETIC CHARACTERISTICS OF A NOVEL ENTITY (2008) (4)
MULTI-ANTIGEN LOADED DENDRITIC CELL (DC) VACCINE FOR THE TREATMENT OF METASTATIC RENAL CELL CARCINOMA (mRCC)-IN-VITRO CORRELATES (1999) (4)
Utility of multiphasic multidetector computed tomography in discriminating between clear cell renal cell carcinomas with high and low carbonic anhydrase-IX expression (2018) (4)
Renal cell carcinoma: physiology, diagnosis, and therapy (1991) (4)
Intraoperative ultrasonography in urologic oncology. (2004) (4)
Artificial Intelligence: Modulating BET Bromodomain Inhibitor ZEN-3694 and Enzalutamide Combination Dosing in a Metastatic Prostate Cancer Patient Using CURATE.AI, an Artificial Intelligence Platform (Adv. Therap. 6/2018) (2018) (4)
Use of carbonic anhydrase IX (CAIX) expression and Von Hippel Lindau (VHL) gene mutation status to predict survival in renal cell carcinoma (2007) (4)
350: Characterization of the MTOR Pathway in Renal Cell Carcinoma and its Use in Predicting Patient Selection for Agents Targeting this Pathway (2005) (4)
LONG TERM FOLLOW UP OF PHASE 2 STUDY OF POMEGRANATE JUICE FOR MEN WITH PROSTATE CANCER SHOWS DURABLE PROLONGATION OF PSA DOUBLING TIME (2009) (4)
Cellular therapy of renal cell carcinoma past, present, future (1997) (3)
Lymph node dissection in patients with kidney cancer: when is it indicated? (2003) (3)
The role of lymphadenectomy in renal cell carcinoma (2004) (3)
TISSUE SPECIFIC EXPRESSION OR A PROSTATE-SPECIFIC ANTIGEN PROMOTER/ENHANCER IN AN ADENOVIRAL VECTOR USED IN A HUMAN PROSTATE CANCER SCID MOUSE MODEL (1999) (3)
THE IMPACT OF GENDER AND AGE IN RENAL CELL CARCINOMA: AGE IS AN INDEPENDENT PROGNOSTIC FACTOR IN WOMEN BUT NOT MEN (2008) (3)
718: The P21 Growth and Apoptosis Regulatory Protein is an Independent Predictor of Survival in Patients with Clear Cell Renal Cell Carcinoma (2006) (3)
492: Prospective Evaluation of Carbonic Anhydrase IX (CAIX) as a Molecular Marker in Metastatic Renal Cell Carcinoma: Interim Results (2007) (3)
Melanoma-associated antigen-A and programmed death-ligand 1 expression are associated with advanced urothelial carcinoma (2019) (3)
741: Microvascular Invasion is Associated with Aggressive Clinicopathological Features and is an Independent Predictor of Survival for Patients with Clear Cell Renal Cell Carcinoma (2006) (3)
Immunology in cancer (1992) (3)
Immunotherapy for metastatic renal-cell carcinoma (1991) (3)
281 Safety and efficacy of partial nephrectomy for all T1 tumours based on an international multicentre experience (2004) (3)
Randomized phase II trial of maintenance sunitinib versus placebo following response to chemotherapy (CT) for patients (pts) with advanced urothelial carcinoma (UC). (2012) (3)
621: Molecular Tumor Grading of Clear Cell Renal Cell Carcinoma Using Protein Expression of the Vascular Endothelial Growth Factor (VEGF) Family (2005) (2)
723: Significance of Tumor Size in Locally Advanced Renal Cell Carcinoma (PT3A): An International Multicenter Experience (2006) (2)
Monoclonal antibodies for the treatment of advanced cancer (2003) (2)
POSITRON EMISSION TOMOGRAPHY (PET), COMPUTED TOMOGRAPHY (CT), AND MONOCLONAL ANTIBODY SCAN (MAb) FOR EVALUATION OF LYMPH NODE METASTASES IN PATIENTS WITH PROSTATE SPECIFIC ANTIGEN (PSA) RELAPSE AFTER TREATMENT FOR LOCALIZED PROSTATE CANCER. (1998) (2)
Evaluation of the prognostic role of co-morbidities on disease outcome in renal cell carcinoma patients (2019) (2)
1246: Nephron-Sparing Surgery does not Undermine Renal Cell Carcinoma-Specific Survival in Patients with PT3 Renal Cell Carcinoma (2007) (2)
PD13-10 PRECLINICAL TRIAL OF SERIAL MITOGEL® INSTILLATIONS INTO THE PELVICALYCEAL SYSTEM OF THE YORKSHIRE SWINE (2016) (2)
A phase I, open label, dose escalation and cohort expansion study to evaluate the safety and immune response to autologous dendritic cells (DC) transduced with AdGMCA9 (DC-AdGMCAIX) in patients with mRCC. (2014) (2)
443 IMPACT OF HISTOLOGY ON CANCER CONTROL AFTER NEPHRON SPARING SURGERY FOR RENAL CELL CARCINOMA (2007) (2)
Receptor activator of NFκB (RANK)-mediated induction of metastatic spread and association with poor prognosis in renal cell carcinoma (2017) (2)
Interferon and kidney cancer: a promise unfulfilled? (1998) (2)
Brain metastasis from renal cell carcinoma: Presentation, recurrence, survival and implications for systemic therapy (2008) (2)
Erratum to “Pomegranate Extracts in the Management of Men's Urologic Health: Scientific Rationale and Preclinical and Clinical Data” (2013) (2)
Immunologic approaches to the treatment of cancer. (1995) (2)
Impact of pathologic tumor characteristics in patients with sarcomatoid renal cell carcinoma. (2011) (2)
Kidney cancer management in 2004: An update for the practicing general urologist (2004) (2)
Growth and antitumor activity of tumor-involved draining lymph node cells versus tumor-infiltrating lymphocytes from patients with renal cell cancer (1987) (2)
216: Low CAIX Expression and Absence of VHL Gene Mutation are Associated with Tumor Aggressiveness and Poor Survival in Patients with Renal Cell Carcinoma (RCC) (2007) (2)
Late relapse of germ-cell tumor. (2003) (2)
The in vitro effects of interleukin-12 upon tumor-infiltrating lymphocytes derived from renal cell carcinoma (2005) (2)
915: Prognosis and Survival of Synchronous Bilateral Renal Cell Carcinoma: A Multicenter Experience (2007) (2)
American studies on suramin therapy in hormone resistant prostate cancer. (1995) (2)
1757: The Prognostic Value of Histologic Subtypes in Renal cell Carcinoma (RCC). A Multicenter Experience in 4063 Patients (2004) (2)
CaPCURE’s fourth meeting: the cutting edge of current prostate cancer research (1997) (2)
A phase I, open-label, dose-escalation and cohort expansion study evaluating the safety and immune response to autologous dendritic cells transduced with AdGMCA9 in patients with metastatic renal cell carcinoma. (2018) (2)
Regulatory effects of interleukin-4 on tumor-infiltrating lymphocytes derived from human renal cell carcinoma. (1992) (2)
Pomegranate Extracts in the Management of Men's Urologic Health: Scientific Rationale and Preclinical and Clinical Data. (2013) (2)
Tumor Infiltrating Lymphocytes in Renal Cell Cancer (1992) (2)
612 PD-0332991, AN INHIBITOR OF CYCLIN-DEPENDENT KINASE 4/6, DEMONSTRATES INHIBITION OF PROLIFERATION IN RENAL CELL CARCINOMA AT NANOMOLAR CONCENTRATIONS AND MOLECULAR MARKERS PREDICT FOR SENSITIVITY (2013) (1)
Monoclonal antibody (MAB) in patients with advanced cancer. (2003) (1)
Urologic oncology: extraordinary opportunities for discovery: highlights from the 2nd annual winter meeting of the society of urologic oncology december 1-2, 2001, bethesda, MD. (2003) (1)
372: Expression Analysis of the Vascular Endothelial Growth Factor (VEGF) Family in Renal Cell Carcinoma: Targeting the VEGF Pathway (2006) (1)
IMMUNOTHERAPY OF PATIENTS WITH METASTATIC RENAL CELL CARCINOMA (RCCa) USING INTERLEUKIN-2 (IL-2) BASED THERAPY ADMINISTERED EITHER ALONE OR WITH IN VIVO PRIMED OR CD8+ SELECTED TUMOR INFILTRATING LYMPHOCYTES (TIL): THE UCLA EXPERIENCE (1993) (1)
169 COMPARISON BETWEEN ELECTIVE AND IMPERATIVE NSS PROCEDURES REGARDING MORBIDITY AND CANCER CONTROL (2007) (1)
AGGRESSIVE SURGICAL RESECTION COMBINED WITH LOW-DOSE RIL 2-BASED ADOPTIVE IMMUNOTHERAPY FOR TREATMENT OF METASTATIC RENAL CELL CARCINOMA (MRCC); SURGICAL BIOLOGY OF A LARGE MULTI-CENTER RANDOMIZED PLACEBO CONTROLLED PHASE II/III STUDY (1999) (1)
POSITIVE SURGICAL MARGINS APPEAR TO HAVE NEGLIGIBLE IMPACT ON THE SURVIVAL OF RENAL CELL CARCINOMAS TREATED BY NEPHRON SPARING SURGERY (2008) (1)
Rethinking staging and treatment for renal cell cancer. (2001) (1)
Use of the UCLA-integrated staging system (UISS) to predict survival after sunitinib treatment for patients with metastatic renal cell carcinoma. (2010) (1)
Heat shock-peptide complex vaccine as adjuvant therapy for high-risk patients with resected renal cell carcinoma (2004) (1)
Prognostic value of gain of chromosome 5q in localized renal cell carcinoma. (2019) (1)
COMPARISON OF 14, 18 AND 20 GAUGE NEEDLES IN EX-VIVO RENAL MASS BIOPSY: A PROSPECTIVE BLINDED STUDY (2008) (1)
Gene expression profiling identifies two distinct papillary renal cell carcinoma (RCC) subgroups of contrasting prognosis. (2006) (1)
Re: efficacy of sunitinib and sorafenib in metastatic papillary and chromophobe renal cell carcinoma. (2008) (1)
Non-clear cell histology in patients with metastatic RCC as a prognostic indicator in the targeted therapy era. (2012) (1)
Clinical, pathological, and molecular correlations of necrosis in the primary tumor of patients with renal cell carcinoma (2004) (1)
What’s hot in the prostate?Think tank workshop on localised prostate cancer (1999) (1)
Interferon Alpha, GM-CSF-Activated T Cells, and IL-6 in Renal Cell Carcinoma. (2001) (1)
Immunological therapy in urological malignancy: Novel combination strategies (2011) (1)
Best of the 2009 AUA Annual Meeting: Highlights from the 2009 Annual Meeting of the American Urological Association, April 25-30, 2009, Chicago, IL. (2009) (1)
1475 FACTORS PREDICTIVE OF DEVELOPING COMPLICATIONS FOLLOWING PRIMARY AND SALVAGE CRYOABLATION OF THE PROSTATE (2012) (1)
Introduction (2008) (1)
1117: The Malignant Potential and Prognosis of Small Renal Tumors (2007) (1)
1331: Expression of Vascular Endothelial Growth Factor A (VEGF-A), VEGF Receptor 1 (VEGFR-1) and VEGFR-2 in Clear Cell and Papillary Renal Cell Carcinoma (RCC): Implications for Therapy (2005) (1)
Predicting Response to Interleukin-2 Therapy Among Patients with Renal Cell Carcinoma (2005) (1)
Case scenario: 69-year-old male with left spermatic cord mass. (2002) (1)
Gene therapy for prostate cancer (1998) (1)
Words of Wisdom. Re: randomized phase III trial on gemcitabine versus mytomicin in recurrent superficial bladder cancer: evaluation of efficacy and tolerance. (2011) (1)
Gene and immune-based therapies for genitourinary malignancies: current status and future prospects. (2000) (1)
NEPHRON SPARING SURGERY (NSS) IS SUPERIOR TO RADICAL NEPHRECTOMY IN PRESERVING RENAL FUNCTION OUTCOME IN TUMORS LARGER THAN 4 CM (2009) (1)
Re: 5-Year Longitudinal Followup after Retropubic and Transobturator Mid Urethral Slings (2015) (1)
NEPHRON-SPARING SURGERY VS. RADICAL NEPHRECTOMY IN PATIENTS WITH RENAL CELL CARCINOMA >7 CM. WITH NO EVIDENCE OF NODAL OR DISTANT METASTATSIS (2008) (1)
HORMONE DEPRIVATION TREATMENT INDUCES SELECTIVE GROWTH OF SUPER AGGRESSIVE PROSTATE CANCER (CaP) CLONES (1999) (1)
319 NEPHRON SPARING SURGERY (NSS) IS SUPERIOR TO RADICAL NEPHRECTOMY IN PRESERVING RENAL FUNCTION OUTCOME: IS IT TRUE EVEN WHEN EXPANDING NSS TUMOUR SIZE INDICATIONS? (2009) (1)
Molecular markers for renal cell carcinoma. (2000) (1)
GENDER SPECIFIC CYTOGENETIC SIGNATURES CAN DISTINGUISH BETWEEN ONCOCYTOMA AND CHROMOPHOBE RENAL CELL CARCINOMA (2008) (1)
Preventing prostate cancer screening versus chemoprevention : pros and cons based on new views of its biology, early events and clinical behaviour (1995) (1)
491: Molecular Tumor Profiling Improves Risk Assessment and Prognostication of Patients with Non-Metastatic Clear Cell Renal Cell Carcinoma (2007) (1)
THE USE OF NEPHRON SPARING SURGERY MAY FAVORABLY IMPACT THE RISK OF NON CANCER RELATED DEATH IN RENAL CELL CARCINOMA SURVIVORS (2009) (1)
91: Comparison Between Open and Laparoscopic Nephron Sparing Surgery. Results From a Multicenter Experience (2006) (1)
EFFECT OF WARM ISCHEMIA TIME ON RENAL DIFFERENTIAL RENAL FUNCTION AFTER RENAL ARTERY CLAMPING FOR LAPAROSCOPIC PARTIAL NEPHRECTOMY (2009) (1)
EDITORIAL: TOWARDS KIDNEY CANCER CRYSTAL BALL. BETTER PROGNOSTICATION OF PATIENTS WITH RENAL CELL CARCINOMA (2001) (1)
VEGF and PDGF Receptors: Biologic Relevance and Clinical Approaches to Inhibition (2009) (1)
The contemporary role on surgery in the management of renal masses (2014) (1)
973 ONCOLOGICAL RESULTS OF NEPHRON SPARING SURGERY FOR HILAR TUMOURS (2007) (0)
SAFETY AND EFFICACY OF PARTIAL NEPHRECTOMY IN TREATING RENAL CELL CARCINOMA.: 474 (2004) (0)
CYTOREDUCTIVE PARTIAL NEPHRECTOMY FOR SMALL PRIMARY TUMORS IMPROVES OVERALL SURVIVAL IN METASTATIC KIDNEY CANCER: MP22‐16 (2017) (0)
Metabolic evaluation of sporadic papillary kidney cancer. (2012) (0)
VHL INDUCES EPITHELIAL TO MESENCHYMAL TRANSITION (EMT) IN AN NF-κB DEPENDENT MANNER (2009) (0)
Prostate-Specific Gene Therapy Using a "Gutless" Adeno-Vector Expressing Antisense TGF-Beta and PSA Promoter-Controlled TNF-Alpha Gene (2002) (0)
655 COMPARISON BETWEEN OPEN AND LAPAROSCOPIC NEPHRON SPARING SURGERY (2007) (0)
Advances in the Treatment of Genitourinary Cancer: Highlights from the 3rd Annual Meeting of the Society of Urologic Oncology, December 13-14, 2002, Washington, DC. (2003) (0)
MP71-02 UTILITY OF CLEAR CELL RENAL CELL CARCINOMA GENE EXPRESSION SUBTYPES IN RISK-STRATIFYING T1 RENAL MASSES (2016) (0)
Setting Rules for Post-ablation and Follow-Up (2013) (0)
RE: QUANTITATIVE POLYMERASE CHAIN REACTION DOES NOT IMPROVE PREOPERATIVE PROSTATE CANCER STAGING (1998) (0)
1337: Endothelial Expression of Vascular Endothelial Growth Factor Receptor 3 (VEGFR-3), but not VEGFR-1 or VEGFR-2, Predicts Survival in Clear Cell Renal Cell Carcinoma (RCC) (2005) (0)
[Adoptive immunotherapy and metastasized cancer of the kidney. Regulator effects of interleukin-4 on tumor infiltrating lymphocytes (TIL)]. (1991) (0)
236 EXTENT OF TUMOR NECROSIS IS AN INDEPENDENT PROGNOSTIC FACTOR FOR PAPILLARY RENAL CELL CARCINOMA (2009) (0)
2002 NON-CLEAR CELL HISTOLOGY IS INDEPENDENTLY ASSOCIATED WITH POOR OUTCOMES IN THE TARGETED THERAPY ERA (2012) (0)
What’s hot in the prostate? (2000) (0)
Metabolic evaluation of sporadic papillary kidney cancer. (2012) (0)
The effect of tobacco exposure in renal cell carcinoma (RCC) overall and cancer-specific survival. (2011) (0)
1480 PERCUTANEOUS CT AND US GUIDED RADIOFREQUENCY ABLATION OF RENAL MASSES: LONG TERM EFFICACY (2010) (0)
UROLOGICAL ONCOLOGY: RENAL, URETERAL AND RETROPERITONEAL TUMORS (2005) (0)
Safety and efficacy of dendritic cell immunotherapy with ad-GMCAIX in an immunocompetent preclinical tumor model of renal cell carcinoma. (2012) (0)
What’s hot in the prostate? (2000) (0)
1332: Complete Reponse to Immunotherapy in Metastatic Renal Cell Carcinoma: Gene Expression and Tissue Microarray Analysis (2005) (0)
What's hot on the prostate? (2000) (0)
Highly Efficient and Consistent Gene Transfer into Dendritic Cells Utilizing a Combination of Ultraviolet-irradiated Adenovirus and Poly ( L-Lysine ) Conjugates 1 (2006) (0)
CARBONIC ANHYDRASE IX AS A NOVEL TARGET FOR DETECTION AND THERAPY OF LOW GRADE UROTHELIAL CELL CARCINOMA (2009) (0)
Bringing Together Basic Scientists and Clinicians in the Fight against Advanced Prostate Cancer 1 (2006) (0)
Innate Immune System between Tumor-Associated Antigen and the Receptor for NY-ESO-1 : Direct Interactions Dendritic Cell Surface Calreticulin (2006) (0)
Use of chromosome 9p status to identify a subset of high-risk localized renal cell carcinoma. (2009) (0)
MP14-03 THE UCLA HISTO-GENETIC RISK CLASSIFICATION (U-HGRC) TO PREDICT OUTCOMES OF LOCALIZED CLEAR-CELL RENAL CELL CARCINOMA (2019) (0)
Use of surgical stapler in adrenal surgery. (1986) (0)
What’s hot in the prostate? (1999) (0)
PREDICTIVE FACTORS FOR LOCAL RECURRENCE AFTER NEPHRON SPARING SURGERY IN RENAL CELL CARCINOMA (2008) (0)
232 A NOMOGRAM PREDICTING DISEASE-SPECIFIC SURVIVAL AFTER NEPHRECTOMY FOR PAPILLARY RENAL CELL CARCINOMA (2009) (0)
MOLECULAR PROGNOSTIC TUMOR PROFILING OF TYPE 1 AND TYPE 2 PAPILLARY RENAL CELL CARCINOMA: RELEVANCE TO THE DEVELOPMENT OF TUMOR-SPECIFIC TARGETED THERAPIES (2008) (0)
449 CAIX LEVEL AND VHL MUTATION DO NOT IMPROVE THE ABILITY TO PREDICT RENAL CELL CARCINOMA-SPECIFIC MORTALITY IN PATIENTS TREATED WITH NEPHRECTOMY (2007) (0)
1750: Prognostic Impact of Chromosomal Alterations in Renal cell Carcinoma Following Surgical Resection (2004) (0)
1792 VALIDATION OF CA-IX POLYMORPHISM RS12553173 AS AN INDEPENDENT PROGNOSTIC FACTOR OF OVERALL SURVIVAL IN METASTATIC CLEAR CELL RENAL CELL CARCINOMA (2010) (0)
1118: Impact of Histology on Cancer Control after Nephron Sparing Surgery for Renal Cell Carcinoma (2007) (0)
51: Morbidity and Clinical Outome of Nephron Sparing Surgery in Relation to Tumor Size and Indication (2006) (0)
The Surgeon, Journal of the Royal Colleges of Surgeons of Edinburgh and Ireland (2012) (0)
1103: Long-Term Survival Following Nephrectomy for Renal Cell Carcinoma: The 15 Year UCLA Experience (2006) (0)
437 GAIN OF CHROMOSOME 8Q IS ASSOCIATED WITH METASTASES AND POOR SURVIVAL OF PATIENTS WITH CLEAR CELL RENAL CELL CARCINOMA (2012) (0)
Advances in adjuvant therapies for renal cell carcinoma (2005) (0)
Chapter 14 – Treatment of Advanced Renal Cell Carcinoma (2005) (0)
P16 12 MP – RADIATION SENSITIVITY AND STUDY OF GLUTATHIONE AND RELATED ENZYMES IN HUMAN RENAL CARCINOMA CELL LINES (1991) (0)
Recognizing the Continuous Nature of Expression Heterogeneity and Clinical Outcomes in Clear Cell Renal Cell Carcinoma (2017) (0)
What’s hot in the prostate? (1998) (0)
738: Pilot Study to Determine the Incidence of Circulating Renal Cell Carcinoma (RCC) Cells in Patients with Metastatic Disease Before and after Treatment with IL-2 Therapy (2006) (0)
Which pathological features of renal cell carcinoma have the greatest prognostic value? (2008) (0)
The UCLA histo-genetic risk classification (U-HGRC) to stratify prognosis of localized clear-cell renal cell carcinoma (2019) (0)
782: Identification of T Cell Clones that Recognize Shared Renal Cell Carcinoma Antigens (2004) (0)
EARLY RENAL FUNCTION OUTCOMES FOLLOWING OPEN VS LAPAROSCOPIC PARTIAL NEPHRECTOMY: HOW DO THEY COMPARE? (2009) (0)
1291: Prognostic Impact of Cytogenetic Findings in Clear Cell Renal Cell Carcinoma: Improved Survival is Seen in Patients with Loss of Chromosome 3P (2007) (0)
Therapeutic strategies, predicting outcomes in patients with renal cell and transitional cell carcinomas. (2000) (0)
The role of obesity in the incidence of lymphatic spread, disease-free, and overall survival: Data from the ARISER clinical trial. (2014) (0)
What’s hot in the prostate? (2001) (0)
Urology in the Desert 2000 the of the (2001) (0)
What’s hot in the prostate? (1999) (0)
Improving the definition of high-risk patients for tumor recurrence from clear-cell renal cell carcinoma – The U-CISS classification (2019) (0)
Nephron-sparing surgery for renal cell carcinoma. (1999) (0)
509 IS BASELINE RENAL FUNCTION A DECISION-MAKING CRITERION FOR CHOOSING AN ABLATIVE TECHNIQUE RATHER THAN A PARTIAL NEPHRECTOMY IN SMALL RENAL MASSES? (2010) (0)
Characterizing Complete Responders to IL-2 Using Gene Expression Analysis and Tissue Array Validation in Patients with Metastatic Renal Cell Carcinoma (2004) (0)
Prognostic value of loss of chromosome 10q in patients with localized renal cell carcinoma. (2019) (0)
LB-S&T-21 A PHASE 2 STUDY OF VESIMUNE®, INTRAVESICAL IMIQUIMOD, FOR THE TREATMENT OF CARCINOMA IN SITU BLADDER CANCER (2016) (0)
Validation of BRCA1 associated protein-1 (BAP-1) as an adverse prognostic factor and investigations into the impact of BAP1 loss on the vascular endothelial growth factor (VEGF) pathway in clear cell renal cell carcinoma (ccRCC) (2017) (0)
Cryosurgical Ablation of the Prostate for Prostate Cancer: Background, Technique and Results (2004) (0)
Editorial comment. (2009) (0)
Molecular Characterization of Androgen Independence to Delay Progression to Hormone Refractory Prostate Cancer (2005) (0)
1071 POOR PROGNOSIS AND ADVANCED CLINICOPATHOLOGICAL FEATURES OF CLEAR CELL RENAL CELL CARCINOMA (CCRCC) ARE ASSOCIATED WITH CYTOPLASMIC SUBCELLULAR LOCALIZATION OF HIF-2α (2013) (0)
This Month in Investigative Urology COMMENTARY ON PROGNOSTIC FACTORS IN RXNAL CELL CARCINOMA (1995) (0)
LineageRelationship BetweenLNCaPand LNCaP-Derived ProstateCancerCell Lines (2004) (0)
304 DC-AD-GMCAIX BASED VACCINE THERAPY IS SAFE AND EFFECTIVE IN IMMUNOCOMPETENT MURINE KIDNEY CANCER TUMOR MODELS (2012) (0)
900: Loss of 3P, Loss of 9P and Trisomy 17 Predict Prognosis in Patients with Papillary Renal Cell Carcinoma (2007) (0)
The UCLA Histo-Genetic Risk Classification (U-HGRC) to predict outcomes of localized clear cell renal cell carcinoma. (2019) (0)
572 CLINICAL, MOLECULAR AND GENETIC CORRELATES OF LYMPHATIC SPREAD IN CLEAR CELL RENAL CELL CARCINOMA (2012) (0)
Abstract No. 176: Percutaneous CT and US guided radiofrequency ablation of renal masses: Long term efficacy (2010) (0)
Biomarkers for early detection and optimized treatment for transitional cell carcinoma. (2001) (0)
418 NEW PROGNOSTIC STRATIFICATION SYSTEM IN LOCALLY ADVANCED RENAL CELL CARCINOMA PATIENTS WHO ARE CANDIDATES FOR ADJUVANT TREATMENT (2010) (0)
Review article Emerging technologies in uroradiologic imaging (2003) (0)
What’s hot in the prostate? Prostate Cancer screening approved in the USA and Highlights from the Annual Meeting of The Western Section American Urological Association (1999) (0)
Session II: Tumor antigens - Prostate cancer antigens and vaccines (2003) (0)
349: Vascular Endothelial Growth Factor Receptor 3 (VEGFR-3) is Preferentially Expressed in Papillary Renal Cell Carcinoma (RCC). (2005) (0)
Immunotherapy and peripheral-blood transplant for metastatic renal cell carcinoma. (2000) (0)
Comprar The Textbook of Kidney Cancer | Gill, Inderbir S. | 9781848826977 | Springer (2010) (0)
680Hematogenous versus lymphatic dissemination: The role of the vascular endothelial growth factor (VEGF) family in the metastatic process of clear cell renal cell carcinoma (2005) (0)
Renal cryoablation: clinical outcomes (2007) (0)
Effect of PD-0332991, a potent and selective inhibitor of cyclin-dependent kinase 4/6, on proliferation in renal cell carcinoma at nanomolar concentrations and prediction of sensitivity by molecular markers. (2013) (0)
682The prognostic value of histologic subtypes in renal cell carcinoma. a multicenter experience in 4063 patients (2005) (0)
87 PAPILLARY RENAL CELL CARCINOMA WITH LOSS OF 9P: A LETHAL GENOTYPE (2010) (0)
645: Vascular Endothelial Growth Factor Receptor 3 (VEGFR-3) is Highly Expressed in the Tumor Endothelium of Clear Cell but not Papillary Renal Cell Carcinoma (RCC): Implications for Therapy (2005) (0)
Carbonic Anhydrase IX: Biology and Clinical Approaches (2009) (0)
137: Evaluation of Pomegranate Polyphenol-Mediated Suppression of Nuclear Factor Kappa b (NF-KB) Activity in Prostate Cancer Cell Lines (2007) (0)
P53 is an independent predictor of tumor recurrence and progression after nephrectomy for patients with localized Renal Cell Carcinoma: Implications for surveillance and adjuvant clinical trials. (2004) (0)
Adoptive Immunotherapy in Renal Cell Carcinoma (2000) (0)
Biological response modifiers in metastatic renal cell carcinoma (1992) (0)
Using PSA kinetics to stratify risk of prostate cancer progression (2005) (0)
What’s hot in the prostate? (1998) (0)
Clinical, pathological, and molecular correlations of necrosis in the primary tumor of patients with renal cell carcinoma. (2004) (0)
Renal Cell Carcinoma: Recent Progress and Future Directions1 (2019) (0)
Renal Cell Carcinoma: Molecular Biology, Immunology, and Clinical Management (2001) (0)
Special Edition EAU-ICUD - Review - Kidney Cancer Basic Research in Kidney Cancer (2011) (0)
The Use of Cytokines, Tumor Infiltrating Lymphocytes, and Gene Therapy in the Treatment of Advanced Renal Cell Carcinoma: The UCLA Experience (1995) (0)
MP36-19 THE ROLE OF OBESITY IN THE INCIDENCE OF LYMPHATIC SPREAD, DISEASE-FREE AND OVERALL SURVIVAL: DATA FROM THE ARISER CLINICAL TRIAL (2014) (0)
THE INCIDENCE OF BENIGN RENAL MASS NEGATIVELY CORRELATES WITH TUMOR SIZE IN MEN ONLY AND IS INFLUENCED BY SURGICAL APPROACH - A MULTICENTRIC STUDY (2009) (0)
779: RENCA/CAIX: A Murine Model of Renal Cell Carcinoma Expressing Carbonic Anhydrase IX (2004) (0)
646: Morbidity of Nephron Sparing Surgery for Hilar Tumors (2007) (0)
TREATMENT OF METASTATIC RENAL CELL CARCINOMA WITH CD8( +) SELECTED TUMOR INFILTRATING LYMPHOCYTES FROM PRIMARY TUMOR NEPHRECTOMY, INTERLEUKIN-2 AND CYTOKINE-PRIMED OR (1997) (0)
The Minimally Invasive Era (2004) (0)
47 Prognostic significance of microvascular invasion in renal clear cell carcinoma (2005) (0)
1255: Potential Role of Postoperative Azotemia in Predicting Response to Interleukin-2 (IL-2) Immunotherapy Following Cytoreductive Nephrectomy for Metastatic Renal Cell Carcinoma (2007) (0)
A nomogram predicting disease-specific survival after nephrectomy for papillary renal cell carcinoma. (2009) (0)
976 MORBIDITY OF NEPHRON SPARING SURGERY FOR HILAR TUMOURS (2007) (0)
What's hot in the prostate? (1997) (0)
Pilot study of VHL mutation analysis to predict response to interleukin-2 in patients with metastatic renal cell carcinoma. (2006) (0)
1099: Prognostic Factors and Long-Term Outcome Following Resection of Renal Cell Carcinoma with Right Atrial Extension: Impact on Survival and Benefits of Immunotherapy (2006) (0)
1656: The Use of Uiss (Ucla Integrated Staging System) to Predict Survival in Renal Cell Carcinoma: An International Multicenter Study in 4202 Patients (2004) (0)
The Isolation and Expansion of Lymphocytes Infiltrating Human Renal Tumors Using Recombinant Interleukin-2; Possible Application for Clinical Use (1987) (0)
Report from the society of urologic oncology: highlights from the fourth annual meeting of the society of urologic oncology, december 5-6, 2003, bethesda, MD. (2004) (0)
979 UISS RISK STRATIFICATION CAN IDENTIFY PATIENTS LESS LIKELY TO BENEFIT FROM CYTOREDUCTIVE NEPHRECTOMY IN THE TARGETED THERAPY ERA (2012) (0)
Cytogenetic andMolecular Tumor Profiling for Type 1 and Type 2 Papillary Renal Cell Carcinoma (2009) (0)
470 EXPRESSION PATTERNS OF SEVEN MOLECULAR MARKERS IN CHROMOPHOBE RENAL CELL CARCINOMA WITH DISTINCT EXPRESSION CHANGES IDENTIFIED IN HIGH-GRADE LESIONS (2013) (0)
Use of CA9 gene single nucleotide polymorphisms to predict prognosis and treatment response of metastatic renal cell carcinoma. (2009) (0)
What’s hot in the prostate? (1999) (0)
PARTIAL NEPHRECTOMY FOR RENAL MASSES: CAN WE APPLY THE QUALITY OF CARE CONCERN ADDRESSED BY THE UROLOGICAL COMMUNITY, TO THE EUROPEAN POPULATION? (2008) (0)
1770 CANCER-SPECIFIC SURVIVAL OUTCOMES OF SUNITINIB TREATMENT IN UISS RISK-STRATIFIED METASTATIC RCC PATIENTS (2011) (0)
CYTOKINE (CK) RELEASE PATTERN UPON AUTOLOGOUS TUMOR STIMULATION OF RENAL TUMOR-INFILTRATING LYMPHOCYTES (TIL): EVIDENCE FOR HIGHER SPECIFIC KILLING BY TNFSECRETORS IN VITRO (1993) (0)
402: Comparison of the Safety and Efficacy of Three Gas-Driven Ultrathin 17-Gauge Cryoneedles with Varying Iceball Geometries in a Live Laparoscopic-Assisted Percutaneous Renal Cryoablation Porcine Model (2006) (0)
CA9 GENE SINGLE NUCLEOTIDE POLYMORPHISMS PREDICT PROGNOSIS AND TREATMENT RESPONSE OF METASTATIC RENAL CELL CARCINOMA (2009) (0)
Update on gene and immune based therapy for urologic malignancy (2001) (0)
768 THE USE OF NEPHRON SPARING SURGERY MAY FAVOURABLY IMPACT THE RISK OF NON CANCER RELATED DEATH IN RENAL CELL CARCINOMA SURVIVORS (2010) (0)
636: Hematogenous Versus Lymphatic Dissemination: The Role of the Vascular Endothelial Growth Factor (VEGF) Family in the Metastatic Process of Clear Cell Renal Cell Carcinoma (2005) (0)
Renal Cell Carcinoma : Recent Progress and Future Directions 1 (2017) (0)
PROTEOMIC IDENTIFICATION AND VALIDATION OF INTERLEUKIN-2 THERAPY RESPONSE IN METASTATIC RENAL CELL CANCER (2008) (0)
ACTIVITY OF GMP GRADE ADENOVIRUS GM-CAIX: A NOVEL MOLECULAR TARGETED VACCINE THERAPY FOR KIDNEY CANCER (2009) (0)
Abstract 1563:In vivosafety and efficacy of a novel dendritic cell based Ad-GMCAIX vaccine with activity against renal cell carcinoma (2012) (0)
Towards kidney cancer crystal ball. Better prognostication of patients with renal cell carcinoma. (2001) (0)
Abstract 2819: Efficacy and safety of the Ad-GM·CAIX dendritic cell-based vaccine in treatingin vivometastatic renal cell carcinoma compared to sunitinib monotherapy and simultaneous vaccine-sunitinib combination therapy (2014) (0)
Cellular and molecular characterization of a helper/inducer T-cell clone with lytic specificity isolated from renal cell carcinoma ascitic fluid (1988) (0)
474 SAFETY AND EFFICACY OF PARTIAL NEPHRECTOMY IN TREATING RENAL CELL CARCINOMA. (2004) (0)
Determining the optimal treatment for advanced bladder cancer. (2001) (0)
2003 ANTITUMOR ACTIVITY OF SUNITINIB VERSUS OTHER FDA-APPROVED TARGETED CANCER AGENTS AGAINST METASTATIC RENAL CELL CARCINOMA IN THE FIRST-LINE SETTING (2012) (0)
Thyroid autoantibodies, telomerase activity, vascular endothelial growth factor, and bone scanning. (1999) (0)
Prostate Cancer Prostate-Specific Antigen following Surgery or Radiation for Phase II Study of Pomegranate Juice for Men with Rising Updated (2006) (0)
CHROMOSOME 9P DELETIONS IN CLEAR CELL RENAL CELL CARCINOMA ARE ASSOCIATED WITH AGGRESSIVE DISEASE (2009) (0)
558 UNCLASSIFIED RENAL CELL CARCINOMA: A MATCHED ANALYSIS OF 85 CASES (2007) (0)
MP71-12 GENOMIC CHARACTERIZATION OF SARCOMATOID TRANSFORMATION IN CLEAR CELL RENAL CELL CARCINOMA (2016) (0)
Prostate Specific Gene Therapy Using a 'Gutless' Adene-Vector Expressing Antisense TGF-Beta and PSA Promotor-Control (1999) (0)
Specific immunotherapy of MUC1-positive adenocarcinomas with a recombinant vaccinia virus expressing MUC1 and IL-2 (2001) (0)
Renal cell carcinoma with retroperitoneal lymph nodes. Impact on survival and benefits of immunotherapy1 (2004) (0)
MP35-06 EFFECTS OF DENDRITIC CELL-BASED AD-GM∙CAIX VACCINE AS MONOTHERAPY OR IN COMBINATION WITH SUNITINIB IN AN IMMUNOCOMPETENT MOUSE MODEL OF METASTATIC RENAL CELL CARCINOMA (2014) (0)
PET IMAGING IN PATIENTS WITH BIOCHEMICAL FAILURE FOLLOWING TREATMENT FOR LOCALIZED PROSTATE CANCER (1998) (0)
EXTENT OF TUMOR NECROSIS IS AN INDEPENDENT PROGNOSTIC FACTOR FOR PAPILLARY RENAL CELL CARCINOMA (2009) (0)
972: Clinical, Pathologic, and Molecular Correlations of Necrosis in the Primary Tumor of Patients with Renal Cell Carcinoma (2005) (0)
Surgery from a US perspective. (1995) (0)
159 PREDICTION OF CANCER-RELATED DEATH IN INCIDENTALLY DIAGNOSED RENAL CELL CARCINOMA (2007) (0)
780: Carbonic Anhydrase IX (CAIX) Expression and VHL Gene Alteration as Predictors of Survival in Renal Cell Carcinoma (2004) (0)
Adenoviral-encoded GMCSF-CAIX antigen fusion gene transfer into human peripheral blood monocyte-derived dendritic cells to induce antigen-specific cellular immune responses: preclinical studies (2008) (0)
Symptom profile and clinical characteristics of metastases in metastatic renal cell carcinoma (2007) (0)
Prognostic and biologic impact of molecular markers in papillary renal cell carcinoma (2007) (0)
193 High cytoplasmic and low nuclear expression of HIF-2α are associated with worse cancer specific survival (CSS) in clear cell renal cell carcinoma (2013) (0)
Impact of pomegranate extract on NF-κΒ activation and emerge of androgen-independent prostate cancer (2008) (0)
Urology in the desert 2000: highlights from the 76th annual meeting of the Western section american urological association. (2001) (0)
MP36-12 VALIDATION OF THE CAIX SCORE AS A PROGNOSTIC BIOMARKER FOR LYMPHATIC SPREAD AND CANCER-SPECIFIC SURVIVAL (2014) (0)
1254: Papillary Renal Cell Carcinoma: Natural Biology and Relevance of Subtyping (2007) (0)
Investigating the association of cytoplasmic and nuclear HIF-2 expression with cancer specific survival (CSS) in clear cell renal cell carcinoma. (2013) (0)
What's hot in the prostate? (2001) (0)
Prostate Focal Therapy (2010) (0)
Long-term survival following nephrectomy for renal cell carcinoma: The 15 year University of California-Los Angeles experience. (2006) (0)
CHROMOSOME 9P DELETIONS IN SMALL CLEAR CELL RENAL CARCINOMA TUMORS (<4 CM) ARE ASSOCIATED WITH SYNCHRONOUS AND METACHRONOUS METASTATIC DISEASE (2009) (0)
Personalized surveillance and prognostication of patients undergoing kidney cancer surgery: The 15-year UCLA experience (2007) (0)
What's hot in the prostate? (2001) (0)
Validation of the CAIX score as a prognostic biomarker for lymphatic spread and cancer-specific survival. (2014) (0)
RENAL FUNCTION AND LOCAL RECURRENCE AFTER PARTIAL NEPHRECTOMY IN SOLITARY KIDNEYS (2009) (0)
Oncology: Adrenal/Renal/Upper Tract/Bladder Fuhrman Grade Provides Higher Prognostic Accuracy Than Nucleolar Grade for Papillary Renal Cell Carcinoma (2010) (0)
Innovative Strategies Proposed at the Western AUA Meeting: Highlights From the Annual Meeting of the Western Section of the American Urological Association September 26-30, 1999, Monterey, California. (2000) (0)
Improving the definition of high-risk patients for tumor recurrence from clear cell renal cell carcinoma: The U-CISS classification. (2019) (0)
Testicular microlithiasis, chemotherapy for stage I seminoma, and chemotherapy for advanced extragonadal germ cell tumors. (2002) (0)
Clinical predictors of sarcomatoid kidney cancer: The results of a UCLA and french UroCCR network collaboration. (2019) (0)
Cryotherapy for localized PCa: Indications and technique (2005) (0)
913 THE IMPACT OF COINCIDENTAL PROSTATE CANCER ON SURVIVAL OF PATIENTS WITH INVASIVE BLADDER CANCER (2009) (0)
Clinical researchRenal cell carcinoma with retroperitoneal lymph nodes: role of lymph node dissection1 (2004) (0)
Immunotherapy and Gene Therapy for Genitourinary Malignancies (1996) (0)
Non-clear cell histology in patients with metastatic RCC as a prognostic indicator in the targeted therapy era. (2012) (0)
Immunotherapy and Chemotherapy for Metastatic Renal Cell Carcinoma (1999) (0)
ABSENCE OF CD44 EXPRESSION IS AN INDEPENDENT PREDICTOR OF POOR OUTCOME FOR PATIENTS WITH UROTHELIAL BLADDER CANCER (2009) (0)
FOR HIGHER SPECIFIC KILLING BY TNF-SECRETORS IN VITRO (1993) (0)
210 LOSS OF CHROMOSOME 3P IN CLEAR CELL RENAL CELL CARCINOMA – ARE THERE DIFFERENCES ACCORDING TO THE UNDERLYING ABERRATION? (2010) (0)
The Role of Combination Biologic Therapy in the Immunotherapeutic Approach to the Treatment of Renal Cell Carcinoma (1992) (0)
MP47-06 BRCA1 ASSOCIATED PROTEIN-1 (BAP-1) LOSS IN CCRCC: MOLECULAR CORRELATIONS AND VALIDATION AS A PROGNOSTIC FACTOR. (2015) (0)
What's hot in the prostate? (1998) (0)

This paper list is powered by the following services:

Other Resources About Arie Belldegrun

en.wikipedia.org

What Schools Are Affiliated With Arie Belldegrun?

Arie Belldegrun is affiliated with the following schools: